welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
completed

A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

key information

study id #: NCT02760264

condition: Duchenne Muscular Dystrophy

status: completed

purpose:

The purpose of this study is to determine whether a new medication called vamorolone is safe and well-tolerated by boys with Duchenne muscular dystrophy (DMD) ages >= 4 and < 7 years old.

intervention:
Vamorolone 0.25 mg/kg/day, Vamorolone 0.75 mg/kg/day, Vamorolone 2.0 mg/kg/day, Vamorolone 6.0 mg/kg/day

mechanism of action: Glucocorticoid to delay decline in muscle strength

results: https://clinicaltrials.gov/ct2/show/results/NCT02760264

last updated: January 07, 2019

study details

start date: June 2016

estimated completion: May 1, 2018

phase of development: Phase 2

size / enrollment: 48

study description:
This study will evaluate the safety and tolerability of a new steroid-like medication called vamorolone in boys with DMD ages >=4 years and < 7 years. Enrolled participants will take the study medication for 14 days followed by a 14 day follow-up period. The potential effectiveness of vamorolone in treating DMD will also be explored.

primary outcomes:

  • Number of participants with treatment-related adverse events as assessed by CTCAE Version 4.03. [ Time Frame: 4 weeks ]

secondary outcomes:

  • Peak plasma concentration (Cmax) of vamorolone [ Time Frame: Day 1 ]
  • Peak plasma concentration (Cmax) of vamorolone [ Time Frame: Week 2 ]
  • Serum pharmacodynamics biomarkers measured by levels of cortisol [ Time Frame: 4 weeks ]
  • Serum pharmacodynamics biomarkers measured by levels of ACTH [ Time Frame: 4 weeks ]
  • Serum pharmacodynamics biomarkers measured by levels of PINP [ Time Frame: 4 weeks ]
  • Serum pharmacodynamics biomarkers measured by levels of osteocalcin [ Time Frame: 4 weeks ]
  • Serum pharmacodynamics biomarkers measured by levels of CTX [ Time Frame: 4 weeks ]
  • Serum pharmacodynamics biomarkers measured by levels of 17-hydroxyprogesterone [ Time Frame: 4 weeks ]
  • Serum pharmacodynamics biomarkers measured by levels of testosterone [ Time Frame: 4 weeks ]
  • Serum pharmacodynamics biomarkers measured by levels of corticosterone [ Time Frame: 4 weeks ]
  • Serum pharmacodynamics biomarkers measured by levels of 11-deoxycortisol [ Time Frame: 4 weeks ]
  • Serum pharmacodynamics biomarkers measured by levels of glucose [ Time Frame: 2 weeks ]
  • Serum pharmacodynamics biomarkers measured by levels of insulin [ Time Frame: 2 weeks ]
  • Serum metabolites of vamorolone [ Time Frame: Week 2 ]

inclusion criteria:
• Subject's parent or legal guardian has provided written informed consent/Health Insurance Portability and Accountability Act (HIPAA) authorization prior to any study-related procedures;
• Subject has a confirmed (by Central Genetic Counselor) diagnosis of DMD as defined as:
-Dystrophin immunofluorescence and/or immunoblot showing complete dystrophin deficiency, and clinical picture consistent with typical DMD, OR
-Identifiable mutation within the DMD gene (deletion/duplication of one or more exons) where reading frame can be predicted as 'out-of-frame', and clinical picture consistent with typical DMD, OR
-Complete dystrophin gene sequencing showing an alteration (point mutation, duplication, other) that is expected to preclude production of the dystrophin protein (i.e. nonsense mutation, deletion/duplication leading to a downstream stop codon), with a typical clinical picture of DMD;
• Subject is >= 4 years and < 7 years of age at time of enrollment in the study;
• Subject is able to complete the Time to Stand Test (TTSTAND) without assistance, as assessed at the Screening and Baseline Visits;
• Clinical laboratory test results are within the normal range at the Screening Visit, or if abnormal, are not clinically significant, in the opinion of the Investigator. (Note: Serum gamma glutamyl transferase [GGT], creatinine, and total bilirubin all must be <= upper limit of the normal range at the Screening Visit);
• Subject has evidence of chicken pox immunity as determined by presence of IgG antibodies to varicella, as documented by a positive test result from the testing laboratory at the Screening Visit; and
• Subject and parent/guardian are willing and able to comply with scheduled visits, study drug administration plan, and study procedures.

exclusion criteria:
• Subject has current or history of major renal or hepatic impairment, diabetes mellitus or immunosuppression;
• Subject has current or history of chronic systemic fungal or viral infections;
• Subject has had an acute illness within 4 weeks prior to the first dose of study medication;
• Subject has used mineralocorticoid receptor agents, such as spironolactone, eplerenone, canrenone (canrenoate potassium), prorenone (prorenoate potassium), mexrenone (mexrenoate potassium) within 4 weeks prior to the first dose of study medication;
• Subject has evidence of symptomatic cardiomyopathy. [Note: Asymptomatic cardiac abnormality on investigation would not be exclusionary];
• Subject is currently being treated or has received previous treatment with oral glucocorticoids or other immunosuppressive agents. [Notes: Past transient use of oral glucocorticoids or other oral immunosuppressive agents for no longer than 3 months cumulative, with last use at least 3 months prior to first dose of study medication, will be considered for eligibility on a case-by-case basis. Inhaled and/or topical corticosteroids prescribed for an indication other than DMD are permitted but must be administered at stable dose for at least 3 months prior to study drug administration];
• Subject has used idebenone within 4 weeks prior to the first dose of study medication;
• Subject has an allergy or hypersensitivity to the study medication or to any of its constituents;
• Subject has severe behavioral or cognitive problems that preclude participation in the study, in the opinion of the Investigator;
• Subject has previous or ongoing medical condition, medical history, physical findings or laboratory abnormalities that could affect safety, make it unlikely that treatment and follow-up will be correctly completed or impair the assessment of study results, in the opinion of the Investigator;
• Subject is taking any other investigational drug currently or has taken any other investigational drug within 3 months prior to the start of study treatment; or
• Subject has previously been enrolled in the study.

study contacts

sponsor: ReveraGen BioPharma, Inc.

investigators: Paula R Clemens, MD

locations: United States, Australia, Canada, Israel, Sweden, United Kingdom

rareRelated